Clinical Trials Logo

Hepatitis B, Chronic clinical trials

View clinical trials related to Hepatitis B, Chronic.

Filter by:

NCT ID: NCT04585165 Recruiting - HIV Infections Clinical Trials

User-friendly HIV Testing and Counseling Services

Start date: October 19, 2020
Phase:
Study type: Observational

Multicenter cohort study of individuals reporting behavioral risks of HIV acquisition, recruited among those presenting for testing for HIV and other sexually transmitted infections. Overarching goal: to study factors associated with uptake of HIV prevention and (re)testing services in medium-sized cities in Thailand. Primary objective: To estimate the incidence of HIV and other sexually transmitted infections (syphilis, chronic hepatitis B and C) among individuals presenting for retesting. Secondary objectives: - To evaluate the uptake of pre-exposure prophylaxis - To assess retention in the study - To evaluate client HIV knowledge - To describe HIV prevalence and characteristics of individuals newly diagnosed with HIV - To describe characteristics of individuals at risk of HIV infection - To assess the quality of the testing and referral services.

NCT ID: NCT04584242 Recruiting - Clinical trials for Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Start date: September 3, 2020
Phase: Phase 4
Study type: Interventional

The clinical study determines the effect of Evogliptin in patients with type 2 diabetes mellitus and chronic hepatitis B to confirm the improvement of hepatic fibrosis.

NCT ID: NCT04568265 Recruiting - Hepatitis B Clinical Trials

A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

Start date: June 3, 2020
Phase: Phase 2
Study type: Interventional

This study is a multicenter, open-label, phase II clinical study in subjects with chronic hepatitis B (CHB), to characterize the safety, tolerability, pharmacokinetic profile and preliminary anti-hepatitis B virus (HBV) efficacy of APG-1387 in combination with entecavir, and to determine the optimal dose of APG-1387 in combination with entecavir.

NCT ID: NCT04565262 Not yet recruiting - Clinical trials for HBeAg Positive Chronic Hepatitis B

Study on Antiviral Therapy for HBeAg-positive Chronic Hepatitis B Patients Aged 1-16 Years

Start date: September 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study is to provide theoretical and real world evidence for the optimization of antiviral treatment by IFN combined with Nucleosides analog in HBeAg positive chronic hepatitis B patients aged 1-16 years,so that the functional cure could be achieved in the greatest extent in pediatric patients

NCT ID: NCT04551261 Completed - Chronic Hepatitis B Clinical Trials

GLS4/RTV and TAF Drug-drug Interaction

Start date: January 10, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of GLS4/RTV combined with TAF in healthy subjects.

NCT ID: NCT04544956 Completed - Hepatitis B Clinical Trials

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

B-Fine
Start date: October 6, 2020
Phase: Phase 2
Study type: Interventional

Hepatitis B virus (HBV) infection, especially chronic, is a significant worldwide medical problem. This is an exploratory study of the therapeutic mechanism of GSK3228836 in participants with chronic hepatitis B (CHB) on stable nucleos(t)ide therapy (which is the first line therapy for CHB). This study is a Phase IIa, multi-center open label exploratory study of the therapeutic mechanism of GSK3228836 in participants with hepatitis B virus e-antigen (HBeAg)-negative CHB on stable nucleos(t)ide therapy using repeat fine needle aspirations of the liver for intrahepatic immunophenotyping. It will investigate the virologic and immunologic correlates of hepatitis B virus surface antigen (HBsAg) loss observed in participants when treated for 12 weeks with 300 milligrams (mg) GSK3228836. Repeat fine needle aspirates of the liver will be performed to enable analysis of liver-resident immune cells to investigate any immunomodulatory properties of GSK3228836 and to study the biology of underlying treatment-associated liver flares. The study will consist of a screening, treatment, and post-treatment follow-up phase. Approximately 20 participants will be enrolled in the study.

NCT ID: NCT04543565 Recruiting - Chronic Hepatitis b Clinical Trials

Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study

Start date: September 2020
Phase: Phase 3
Study type: Interventional

This is a phase three study to evaluate the safety and efficacy of Pradefovir treatment in chronic hepatitis B patients. Subject will be randomized to Pradefovir group and TDF group at a ratio of 2:1. Treatment duration will be 96w in randomization and followed by 48w in open. The interim analysis will be conducted when all subject completed the first 48-week treatment.

NCT ID: NCT04539652 Completed - Chronic Hepatitis B Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients

Start date: September 20, 2018
Phase: Phase 4
Study type: Interventional

This study was designed to evaluate the rate of subjects with HBV DNA less than 20 IU/mL after taking TenofoBell® tablet for 48 weeks

NCT ID: NCT04538651 Recruiting - Clinical trials for Hepatitis B, Chronic

A Cross-sectional Study for Renal Function of Patients With Chronic Hepatitis B in China

Start date: August 31, 2020
Phase:
Study type: Observational

1. To acknowledge the prevalence of renal insufficiency and kidney-related diseases in patients with chronic hepatitis B in China through epidemiological surveys in outpatient clinics of about 150 hospitals across the country; 2. To analyze the related factors of renal insufficiency and kidney-related diseases in domestic patients with chronic hepatitis B from the aspects of demographic characteristics, family history, antiviral treatment, nephrotoxic drug use history, etc.

NCT ID: NCT04536532 Suspended - Clinical trials for Hepatitis B, Chronic

Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study

Start date: October 12, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The Safety, Tolerability, Pharmacokinetics and antiviral activity Study of Anti hepatitis B virus treatment drug HEC121120 in Healthy subjects and in patients with chronic hepatitis B